the turnover and degradation of sulfated compounds, mostly complex molecules that are hydrolyzed in lysosomes in concert with acidic glycosidases. Functional correlation among sulfatases is reflected in a high degree of amino acid sequence similarity along the entire
fecting bone and cartilage due to arylsulfatase E (ARSE) enhancing effect of the SUMF1 gene product on the activity of sulfatases. The latter finding has direct clinical deficiency (Franco et al., 1995) . ARSE is also implicated in a drug-induced human malformation syndrome, Warimplications for the therapy of at least eight human diseases caused by sulfatase deficiencies. farin embryopathy, caused by inhibition of the enzymatic activity due to in utero exposure to warfarin during pregnancy (Franco et al., 1995) .
In an intriguing human monogenic disorder, multiple Results sulfatase deficiency (MSD), all sulfatase activities are simultaneously defective (Austin, 1966; Kolodny and The Gene Mutated in MSD Maps to Chromosome 3p26 Fluharty, 1995; Hopwood and Ballabio, 2001 ). Consequently, the phenotype of this severe multisystemic disTo identify the chromosomal location of the gene mutated in MSD, we attempted to rescue the deficient activease combines the features observed in individual sulfatase deficiencies. The posttranslational modification ity of sulfatase enzymes by functional complementation via microcell-mediated chromosome transfer. A panel which is required for the activity of all sulfatases was found to be defective in a cell line from a patient with of human/mouse hybrid cell lines (Cuthbert et al., 1995) containing individual normal human chromosomes MSD, suggesting that this disorder is caused by a mutation in a gene, or genes, implicated in the cysteinetagged with the dominant selectable marker HyTK was used as the source of donor human chromosomes and to-formylglycine conversion machinery (Schmidt et al., 1995) . In spite of an intense biological and medical interfused to an immortalized cell line from a patient with MSD. All 22 human autosomes were transferred one by est, efforts aimed at the identification of the MSD gene(s) have been hampered by the rarity of MSD patients and one to the patient cell line and hybrids were selected in hygromycin and HAT-containing medium. Approxiconsequent lack of suitable familial cases to perform genetic mapping. mately 25 surviving colonies were picked in each of the 22 transfer experiments. These were grown separately Here we report the identification of the gene mutated in MSD by means of functional complementation using and harvested for subsequent enzymatic testing. ARSA, ARSB, and ARSC activities were tested for each of the microcell mediated chromosome transfer. Our findings provide insight into a novel biological mechanism affectapproximately 440 clones (20 ϫ 22). This analysis clearly indicated that sulfatase activities of several clones deriving an entire family of proteins in distantly related organisms. In addition to identifying the molecular basis of a ing from the chromosome 3 transfer were significantly higher compared to those of clones from all other chrorare genetic disease, our data demonstrate a powerful Figure 1A) . However, some of the clones from genotyped using a panel of 31 polymorphic microsatellite markers spanning the entire chromosome. All clones the chromosome 3 transfer had low sulfatase activities. To verify whether each clone had an intact human chrodisplaying high enzymatic activities retained chromosome 3p26 markers from the donor chromosome. Statismosome 3 from the donor cell line, we used a panel of 23 chromosome 3 polymorphic genetic markers that are tical analysis for radiation hybrid mapping was performed as previously described (Boehnke et al., 1991). evenly distributed along the length of the chromosome and previously selected on the basis of having different Markers D3S1297, D3S1304 and D3S1263 located in this region showed maximum lod scores of 12.51, 4.76. alleles between donor and patient cell lines. This allowed us to examine for the presence of the donor chromoand 9.39 at the estimated distances of 0.30, 0.00, and 0.45 R (rays), respectively. A higher resolution analysis some and to identify possible loss of specific regions due to incidental chromosomal breakage. As shown in using additional markers from the same region, performed on selected hybrid clones, mapped the putative Figure 1B , each clone that had high enzymatic activity retained the entire chromosome 3 from the donor cell line, location for the complementing gene between markers D3S3630 and D3S2397 ( Figure 1C ). whereas clones with low activities had lost the entire chromosome on the basis of the absence of chromosome 3 alleles from the donor cell line. The latter clones Identification of the Gene Mutated in MSD We tested genes from the genomic region shown in probably retained a small region of the donor chromosome containing the selectable marker gene that enabled Figure 1C for mutations in MSD patients. Each exon including splice junctions was PCR-amplified and anathem to survive in hygromycin-containing medium. These data indicate that a normal human chromosome 3 was lyzed by direct sequencing. Mutation analysis was performed on twelve unrelated affected individuals; six preable to complement the defect observed in the MSD patient cell line.
mosomes (
viously described MSD patients and six unpublished cases. Several mutations were identified from our MSD Finally, to determine the specific chromosomal region containing the gene responsible for the complementing cohort in the anonymous cDNA sequence PSEC0152 (Genbank accession number AK075459), corresponding activity, we used a Neo-tagged chromosome 3 hybrid, which often undergoes chromosomal breakage spontato a gene of unknown function, strongly suggesting that this was the gene involved in MSD. Each mutation was neously (Imreh et al., 1997). In addition, we performed irradiation microcell-mediated chromosome transfer of found to be absent in 100 control individuals, thus excluding the presence of sequence polymorphisms. On HyTK-tagged human chromosomes 3 (Hunt, 1996) . One hundred and fifteen chromosome 3 irradiated hybrids the basis of the functional data reported below and of previous studies on the biochemical defect in MSD were tested for ARSA, ARSB, and ARSC activities and Figure 2A . Additional confirmatory mutation analysis was performed on reverse transcribed patients' RNAs, pears to be conserved in all vertebrates analyzed, but absent in more distantly related species. particularly in those cases in which genomic DNA analysis revealed the presence of a mutation in or near a Figure 3A shows the amino acid sequence alignment of proteins encoded by the SUMF1 gene homologs in splice site, possibly affecting splicing. An example of such mutation resulting in exon skipping is shown in a selected number of species, including Homo sapiens, Mus musculus, Fugu rubripes, Drosophila melanogas- Figure 2B . The types and locations of each of the mutations identified are shown in both Figure 2C and Table ter, Anopheles gambiae, and two bacterial species, Streptomyces coelicolor and Corynebacterium effi-1. In three instances, different patients (case 1 and 4, case 6 and 9, and case 11 and 12 in Table 1) were found ciens. A high degree of sequence similarity was observed along the entire length of protein sequences, to carry the same mutation. Two of these patients (case 11 and 12) originate from the same town in Sicily, sugwith the exception of the hydrophobic N-terminal region. The region between the amino acids 303 and 351 of the gesting the presence of a founder effect that was indeed confirmed by haplotype analysis (data not shown).
human SUMF1-encoded protein differs from the corresponding region of SUMF2. Interestingly, this region of SUMF1-encoded proteins contains three regularly The SUMF1 Gene and Protein The SUMF1 gene contains nine exons and spans apspaced cysteine residues which are absent from the SUMF2-encoded proteins. The spacing of these cysproximately 106 kb. The consensus SUMF1 cDNA sequence (2130 bp), obtained by comparing several cDNA teines is reminiscent of the domain responsible for sulfatase modification found in the bacterial sulfur binding clones with the genomic sequence, is predicted to encode a 374 amino acid protein. No previously described proteins. The human SUMF2 sequence appears to be more similar to the corresponding murine and Fugu hodomains of known function could be detected in the coding sequence. A highly hydrophobic region, entirely mologs than to the human SUMF1 sequence, thus suggesting that a second gene was generated early during encoded by the first exon, was identified at the N terminus, suggesting the presence of a leader peptide possivertebrate evolution and evolved independently from the first gene. This is also evident from the analysis of bly responsible for proper subcellular localization. Consensus cDNA sequences of SUMF1 gene homologs the phylogenetic tree ( Figure 3B ). In silico analysis of ESTs represented in various tisfrom other species were also assembled. The predicted start codon of the human SUMF1 gene is conserved in sues predicts a ubiquitous expression pattern of SUMF1 with a higher abundance in kidney. This was confirmed the mouse homolog. Sequence comparison also identified the presence of a SUMF1 gene paralog located on experimentally by Northern blot analysis showing a Table 2 ). The disease-associated mutations result in sulfatase deficiency, thus demonstrating that SUMF1 SUMF1/ARSA ratios) resulted in an increase of ARSA activity reaching a plateau at high SUMF1/ARSA ratios is an essential factor for sulfatase activity.
( Figure 5D ). Competition of the different sulfatases for the modification machinery was evident from the obser-SUMF1 Enhancing Effect on Sulfatase Activities To study the effect of SUMF1 on sulfatase activities, vation that simultaneous overexpression of multiple sulfatase cDNAs resulted in a lower increase of each indiwe overexpressed ARSA, ARSC, and ARSE cDNAs in various cell lines with and without cotransfection of vidual sulfatase activity as compared to the increase observed when a single sulfatase was overexpressed SUMF1 cDNA and measured sulfatase activities. Overexpression of sulfatase cDNAs in Cos-7 cells resulted in ( Figure 5E ). a moderate increase of sulfatase activity, while a striking synergistic increase (20-to 50-fold) was observed when Functional Conservation of SUMF1 during Evolution both a sulfatase and SUMF1 cDNAs were coexpressed ( Figure 5A ). A similar, albeit lower, effect was observed To test for functional conservation of SUMF1 during evolution, we coexpressed human ARSA, ARSC, and in three additional cell lines, HepG2, HEK293, and U2OS ( Figure 5B ).
ARSE cDNAs with both the murine and the Drosophila SUMF1 homologs. Both of them enhanced all three huThe enhancing effect SUMF1 has on sulfatase activities was found to be dependent on both time after transman sulfatases, with the Drosophila SUMF1 being less efficient ( Figure 5F ). These data demonstrate a high defection and on the amount of SUMF1 cDNA. A time- (F) Murine SUMF1, Drosophila SUMF1, and human SUMF2 enhance human sulfatase activities. Cos-7 cells were cotransfected with either SUMF1 ϩ ARSA, mSUMF1 ϩ ARSA, dSUMF1 ϩ ARSA, or SUMF2 ϩ ARSA cDNAs at 1:1 ratio. Cos-7 cells were also single transfected with ARSA cDNA or with the empty vector. Similarly, cotransfections were performed using either ARSC or ARSE cDNAs instead of ARSA. Enhancing effects on human ARSA, ARSC, and ARSE enzymatic activities were observed with both the murine and Drosophila SUMF1 genes. A much lower enhancing effect was also detected with SUMF2.
gree of functional conservation of SUMF1 during evoluDiscussion tion, suggesting a critical biological importance of its function. A similar and consistent, albeit much weaker, The study of rare genetic diseases sometimes leads to the discovery of novel biological mechanisms and effect was observed by using the SUMF2 gene, suggesting that its protein product also has a sulfatase metabolic pathways. This has been the case for MSD. ., 1985) .
The discovery that sulfatases from a patient with MSD could be drawn between the type of mutation and the severity of the phenotype; however, more detailed cliniwere inactive because they did not undergo the required posttranslational modification (Schmidt et al., 1995) was cal and biochemical studies are needed in the patients to address this issue. Many patients were found to be the first demonstration of a biochemical defect in this disorder. However, nothing was known about the encompound heterozygotes, carrying two different mutations. However, a founder effect was identified for one zyme(s) involved in this protein modification machinery in eukaryotes and, therefore, the molecular basis of MSD mutation originating from a small town in Sicily. has remained a mystery for many years. vectors containing SUMF1 cDNAs carrying two of the Furthermore, a residual sulfatase activity, of variable mutations found in the patients, R327X and ⌬ex3, were degree, was observed in all MSD patients studied. This used and no significant increase of enzyme activity was could be due to hypomorphic (i.e., partial loss of funcobserved. tion) mutations in MSD patients allowing for a residual Our mutational and functional data strongly suggest function. Alternatively, an additional gene might exist that the SUMF1-encoded protein is responsible for the which partially compensates for the total loss of function previously described posttranslational modification reof the gene involved in MSD. The cloning of SUMF1 quired for sulfatase activity (Schmidt et al., 1995) . Rehas now allowed some of these important issues to be cently, we became aware that another group indepensolved. dently discovered the same gene using a biochemical approach based on an in vitro assay, enabling them to measure the cysteine to formylglycine modification Molecular Basis of MSD Based on the hypothesis that the disease gene should , this issue of Cell). On the basis of our data and of those of the accompanying paper, we be able to complement the enzymatic deficiency in a patient cell line, we performed microcell-mediated chronamed the protein encoded by SUMF1 formylglycinegenerating enzyme (FGE). mosome transfer to an immortalized cell line from a patient with MSD. This technique has been successfully The SUMF1 gene shows an extremely high degree of sequence conservation across all distantly related used for the identification of genes whose predicted function could be assessed in cell lines (e.g., by measurspecies analyzed, from bacteria to man. We provide evidence that the Drosophila homolog of the human ing enzymatic activity or by detecting morphologic features). To address the problem of stochastic variability SUMF1 gene is able to activate overexpressed human sulfatases, proving that the observed degree of seof enzyme activity, we measured the activities of three different sulfatases (ARSA, ARSB, and ARSC) in the quence similarity of the SUMF1 genes of distantly related species correlates with a striking functional concomplementation assay. The results of chromosome transfer clearly indicated mapping of the complementservation. A notable exception is yeast, which appears to lack the SUMF1 gene as well as any sulfatase-encoding gene to chromosome 3. Subregional mapping to chromosome 3p26 was achieved by generating a radiaing genes, indicating that sulfatase function is not required by this organism and suggesting the presence tion hybrid panel.
Once the critical genomic region was defined, the of a reciprocal influence on the evolution of SUMF1 and sulfatase genes. SUMF1 gene was identified by mutation analysis in pa-FGE, the protein product of the SUMF1 gene, belongs to a previously identified protein family classified as "unknown function," indicating that no known functional domains could be assigned to any of these proteins in any species. Interestingly, there are two homologous genes, SUMF1 and SUMF2, in the genomes of all vertebrates analyzed, including humans. As evident from the phylogenetic tree, the SUMF2 gene appears to have evolved independently from the SUMF1 gene. In our assays, the SUMF2 gene is also able to activate sulfatases; however, it does it in a much less efficient manner compared to the SUMF1 gene. This may account for the residual sulfatase activity found in MSD patients and suggests that a complete deficiency of all sulfatases might be lethal. At the moment we cannot rule out the possibility that SUMF2 has an additional, yet unknown, function. The variability observed between different cell lines are currently being performed for two congenital disorders due to sulfatase deficiencies, MPSII (Hunter synmay be due to different levels of endogenous SUMF1. Consistent with these observations, we found that the drome) and MPSVI (Maroteaux-Lamy syndrome), and will soon be extended to a large number of patients. expression of the SUMF1 gene varies among different tissues, with significantly higher levels in kidney and Toward the goal of achieving an efficient production of active sulfatases for enzyme replacement in humans, liver. This may have important medical implications, as tissues with low SUMF1 gene expression levels may the SUMF1 gene was transiently expressed in two different cell lines stably overproducing either iduronate-2-be less capable of effectively modifying overexpressed sulfatase proteins. It will be important to test whether sulfatase (I2S) or N-acetyl-galactosamine-6-sulfatase (GALNS), which are the enzymes defective in Hunter SUMF1 activity is truly rate limiting in some tissues in vivo. Together, these data suggest that the function of and Morquio A syndromes, respectively. These cell lines were developed for mass enzyme production to be used the SUMF1 gene has evolved to achieve a dual regulatory system, with each sulfatase being controlled by an in enzyme replacement trials (Transkaryotic Therapies, Inc.). A significant increase of activity was observed for individual mechanism, responsible for the mRNA levels of each structural sulfatase gene, and by a common both enzymes, although of a different magnitude: 50-fold for GALNS and 5-fold for I2S (data not shown). mechanism controlled by the levels of SUMF1. In addition, SUMF2 provides partial redundancy for sulfatase These experiments were performed as part of a collaborative effort between Dr. Mike Heartlein, Transkaryotic modification. Figure 6 shows a model to explain SUMF1 enhancing effect on sulfatase activities, underscoring Therapies Inc., Dr. Kurt von Figura's laboratory, and our group. Based on these observations, future mass the importance of having sufficient amounts of SUMF1-encoded protein to reach complete activation of overexsulfatase production efforts will certainly involve coexpression of SUMF1. pressed sulfatases.
Impact on the Therapy of Diseases Due to Sulfatase Deficiencies
These data have profound implications for the effecWe envision that SUMF1 may also be used, synergistically with single sulfatase genes, in gene therapy efforts tiveness of mass production of active sulfatases to be utilized in enzyme replacement therapy. (pH 8) in 0.2 ml incubation volume. ARSE was assayed by incubating Briefly, the donor cells were plated on plastic bullets in DMEM cell homogenates with 0.2 mM 4-methylumbelliferyl sulfate in 0.5% containing 10% fetal bovine serum and hygromycin B (400 U; CalbioTriton X-100, 75 mM NaCl, 0.05 mM Tris-HCl buffer (pH 7.5) in 0.2 chem). After 24 hr, colcemid solution was added at 0.05 g/ml final ml incubation volume. concentration. Micronucleation was allowed to occur for 48 hr. The For ARSB, ARSC, and ARSE assays, the reactions were stopped micronucleated cells were then washed with PBS, incubated for 30 with 2 ml glycine-carbonate buffer pH (10.7) and fluorescence was min at 37ЊC in DMEM without serum containing 10 g/ml Cytocharead at 365 nm (excitation) and 450 nm (emission) on a Turner lasin B, and centrifuged in the same medium in a prewarmed centrifluorometer. fuge at 34ЊC for 30 min at 15,000 rpm. The crude microcell pellet was resuspended in serum-free ␣MEM medium and filtered through Northern Blot Analysis 8 m and 5 m filters. The purified microcells were spun at 2000 A membrane carrying a panel of human polyA ϩ RNA was hybridized rpm for 10 min and resuspended in serum-free ␣MEM medium. The with 32 P-labeled SUMF1 and ␤-ACTIN probes according to the manmicrocell suspension was added to the plate containing the recipient ufacturers instructions (Clontech). cells along with phytohemoagglutinin P at 200 g/ml final concentration and incubated for 15 min at 37ЊC. Microcells were fused with Immunofluorescence Staining 50% PEG for 55 s, washed three times with serum-free ␣MEM meCos-7 cells seeded on Lab-Tek Chamber Slide (Nalge Nunc Internadium, and incubated in 15% FCS ␣MEM medium. After 48-72 hr, tional) were transfected with SUMF1-Myc cDNA. Forty-eight hours the fused cells were selected in hygromycin B (400 U/ml) and HAT after transfection, cells were fixed with 100% methanol for 5 min at 1ϫ. MMCT was performed as described above using the Neo-Ϫ20ЊC, permeabilized with 0.2% Triton X-100 in phosphate-buffered tagged human:mouse chromosome 3 hybrid GM11713 (Coriell Cell saline for 15 min at room temperature, and processed for immunofluRepositories) as donor cell line. Selection was performed with G418 orescence staining. Cells were incubated with mouse anti-Myc poly-(300g/ml) and HAT1ϫ.
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